Mitiglinide 207844-01-7

inquire about Mitiglinide
Mitiglinide

Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes. Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) K(ATP) channels in pancreatic beta-cells.

Dosage

Mitiglinide is delivered in tablet form.

read more [+]
Systematic (IUPAC) name: (2S)-2-benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol- 2-yl]-4-oxobutanoic acid
Mitiglinide CAS number: 207844-01-7
ATC code: A10BX08
PubChem: 121891
DrugBank:
Formula: C19H25N1O3
Molecular mass: 315.41 g/mol
Mitiglinide Assay/Purity: Typically NLT 98%
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.